EUCTR2008-002230-30-BG进行中（未招募）不适用
A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236 as an Oral Tablet in Patients with Moderate to Severe COPD. - CERA
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of informed consent prior to any study specific procedures
- •2. Men, or postmenopausal/hysterectomised/oophorectomised women = 40 years of
- •age. Postmenopausal women defined as being amenorrhoeic for at least 24 months.
- •3. A minimum weight of 50 kg
- •4. Diagnosis of COPD for at least 1 month
- •5. FEV1 30 to 80 % of the predicted normal value (post-bronchodilator) and
- •post-bronchodilator FEV1/FVC < 70 %
- •6. Current or ex-smokers with a smoking history of at least 10 pack-years (1 pack
- •year = 20 cigarettes smoked per day for one year. For cigars, cigarillos etc see
- •further information in eCRF instructions)
- •7. Patients that are able to discontinue non-allowed concomitant medication
- •8. Recent or current use of short-acting rescue/reliever medication.
- •For inclusion in the study at Visit 3 the patients must fulfil the following criterion:
- •1. A score = 1 on Breathlessness score on at least half of the numbers of days during
- •the run-in period. (At least 6 days with a score = 1 on Breathlessness score are
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any clinically relevant disease or disorder (past or present), which, in the opinion
- •of the investigator, may either put the patient at risk because of participation in
- •the study, or influence the results of the study, or the patient’s ability to participate
- •in the study
- •2. Any current respiratory tract disorder other than COPD, which is considered by
- •the investigator to be clinically significant or may influence the result of the study
- •3. A clinical suspicion of active or latent tuberculosis defined as any of the following:
- •a) positive tuberculosis test (such as Quantiferon-GOLD or Mantoux-test
- •(>5 mmin unvaccinated individuals and >10 mm in individuals with previous
- •BCG-vaccination),
- •b) suspicion of active or latent tuberculosis on chest X-ray taken within last 12
- •c) past medical history of tuberculosis
- •4. Malignancy or neoplastic disease within the last 5 years, other than treated
- •basal/squamous cell skin cancer or treated cervical cancer in situ
- •5. Disease history suggesting reduced or abnormal immune function
- •6. Any clinically relevant abnormal findings in physical examination, clinical
- •chemistry, haematology, urinalysis, vital signs or ECG at baseline, which, in
- •the opinion of the investigator, may put the patient at risk because of his/her
- •participation in the study
- •7. Patients with glomerular filtration rate less than 30 mL/min, calculated as
- •creatinine clearance from serum-creatinine according to the Cockcroft and Gault
- •f o rm ula: (C Lcre atinine (ml/min)= constant x (140-a g e) x w eight (kg)/se rum
- •creatinine (µM). Constant being 1.23 for men and 1.04 for women
- •8. Known HIV infection, or patients who belong to a high risk group for HIV
- •9. Increased Cardiac Troponin I>Upper Limit of Normal (ULN) at Visit 2
- •10. Patients with underlying musculoskeletal symptoms of unknown origin and
- •patients with shoulder girdle musculoskeletal symptoms or Dupuytrens contracture
- •symptoms as judged by the Investigator
- •11. Requirement for regular oxygen therapy
- •12. An exacerbation of COPD (treatment with oral or parenteral antibiotics and/or oral
- •or parenteral glucocorticosteroids (GCS) and/or hospitalization related to COPD)
- •within 30 days of Visit 2, or during the run-in period
- •13. Use of oral or parenteral glucocorticosteroids within 30 days prior to Visit 2, or
- •during the run-in period
- •14. Known or suspected hypersensitivity to study therapy or excipients of the
- •investigational product
- •15. History of, or, current alcohol or drug abuse, as judged by the investigator
- •16. Scheduled in-patient hospitalization during the course of the study
- •17. Donation of blood within 3 months prior to Visit 2
- •18. Vaccination within 2 weeks prior to Visit 2
- •19. Previous randomisation of treatment in the present study
- •20. Participation in another clinical study involving drug administration during the last
- •3 months before Visit 2
- •21. Involvement in the planning and/or conduct of the study (applies to both
- •AstraZeneca staff and/or staff at the study site)
- •22. Clinical judgement by the investigator that the patient should not participate in
- •If the patient participates in the genetic part of the study these exclusion criteria apply as well:
- •23. Whole blood transfusion within 120 days of the date of genetic sample collection
- •24. Previous bone marrow transplant
研究者
相似试验
进行中（未招募）
不适用
A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236 as an Oral Tablet in Patients with Moderate to Severe COPD.Chronic Obstructive Pulmonary Disease (study conducted in men or women, not of child bearing potential, aged 40 years or above).MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-002230-30-HUAstraZeneca AB60
进行中（未招募）
不适用
A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236 as an Oral Tablet in Patients with Moderate to Severe COPD. - CERAChronic Obstructive Pulmonary Disease (study conducted in men or women, not of child bearing potential, aged 40 years or above).MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-002230-30-FIAstraZeneca AB60
进行中（未招募）
1 期
A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236 as an Oral Tablet in Patients with Moderate to Severe COPD.Chronic Obstructive Pulmonary Disease (study conducted in men or women, not of child bearing potential, aged 40 years or above).MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-002230-30-SKAstraZeneca AB60
进行中（未招募）
不适用
A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236 as an Oral Tablet in Patients with Moderate to Severe COPD.EUCTR2008-002230-30-DEAstraZeneca AB60
进行中（未招募）
1 期
Treatment of excessive sleepiness in adult patients with obstructive sleep apnea; to increase the ability to stay awake throughout the day.Treatment of excessive sleepiness in adult patients with obstructive sleep apneato increase the ability to stay awake throughout the day.MedDRA version: 19.0Level: LLTClassification code 10055577Term: Obstructive sleep apnea syndromeSystem Organ Class: 100000004855EUCTR2014-005515-16-FIJazz Pharmaceuticals Inc.200